TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Hernández-Romero D
  • Jover E
  • Martínez CM
  • Andreu-Cayuelas JM
  • Orenes-Piñero E
  • Romero-Aniorte AI
  • Casas T
  • Cánovas S
  • Valdés M
  • de la Morena G

Grups d'Investigació

Abstract

BackgroundHypertrophic cardiomyopathy (HCM) is characterized by inappropriate hypertrophy, myocyte disarray and increased interstitial fibrosis. The tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a cell surface cytokine with biological activities including stimulation of cell growth, induction of inflammatory cytokines and stimulation of apoptosis. There are controversial data about the potential role of TWEAK in different cardiovascular pathologies. NT-proBNP is an established biomarker of myocardial wall stress, associated with poor functional class in HCM. We hypothesized that effort capacity in patients with HCM could be related to serum levels of these biomarkers. Materials and methodsWe included 40 haemodynamic stable HCM patients and 53 healthy controls with similar sex and age. We studied exercise capacity by maximal oxygen consumption in a limited treadmill exercise test. TWEAK and NT-proBNP were assayed by ELISA method and automated Elecsys (R) platform, respectively. We obtained 46 samples of myocardial tissues by septal myectomy in patients with HCM and evaluated myocardial fibrosis, immunoreaction with TWEAK antibody and apoptosis with TUNEL assay. ResultsWe found raised TWEAK and NT-proBNP serum levels in patients when compared with control levels (both P<0001). In a multivariate analysis, TWEAK and NT-proBNP levels, as well as sex, remained independently associated with the effort capacity (all P<005). We found an association between immunoreaction degree and the degree of myocardial fibrosis (P=0021), as well as apoptosis (P=0002) in the tissue samples from patients undergoing septal myectomy. ConclusionsTWEAK and NT-proBNP levels are biomarkers of disease severity independently associated with the effort capacity in patients with HCM.

Dades de la publicació

ISSN/ISSNe:
0014-2972, 1365-2362

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION  WILEY

Tipus:
Article
Pàgines:
179-186
PubMed:
25524713
Factor d'Impacte:
1,232 SCImago
Quartil:
Q1 SCImago

Cites Rebudes en Web of Science: 4

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Effort capacity; hypertrophic cardiomyopathy; myocardial fibrosis; NT-proBNP; TWEAK

Campos d'Estudi

Projectes associats

REDINSCOR

RD06/0003/1001 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2008

RED DE BIOBANCOS (BIOBANCOS)

RD09/0076/00021 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010

REGISTRO MULTICÉNTRICO DE PACIENTES HOSPITALIZADOS POR INSUFICIENCIA CARDÍACA AGUDA (REDINSCOR II).

RD12/0042/0003 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

RED DE TERAPIA CELULAR (TERCEL)

Investigador Principal: PILAR SEPÚLVEDA SANCHIS

RD12/0019/0025 . INSTITUTO DE SALUD CARLOS III; FUNDACION FORMACION E INVESTIGACIÓN SANITARIA MURCIA (IMIB); FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

HECATOS. HEPATIC AND CARDIAC TOXICITY SYSTEMS MODELLING.

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

602156_HECATOS_PE_FP7-HEALTH-2013-INNOVATI . 2013

MECANISMOS MOLECULARES Y CELULARES DE LAS CELULAS MESENQUIMALES HUMANAS Y DE LAS CELULAS CARDIACAS RESIDENTES DEL ADULTO EN EL ENTORNO CARDIACO ISQUEMICO Y EL NICHO HEMATOPOYETICO.

Investigador Principal: PILAR SEPÚLVEDA SANCHIS

PI13/00414 . INSTITUTO DE SALUD CARLOS III . 2014

DESARROLLO Y VALIDACIÓN DE UN MODELO DE ISQUEMIA MIOCÁRDICA PRECOZ MEDIANTE ESPECTROMETRÍA DE MASAS.

Investigador Principal: BEGOÑA IGUAL MUÑOZ

APM-39/15 . 2015

ESTUDIO DE DURABILIDAD DEL TRIFECTA.

Investigador Principal: JOSÉ ANASTASIO MONTERO ARGUDO

CS-10-012-EU-TV . 2011

ESTUDIO DE LA TOXICIDAD EN PLASMA INDUCIDA POR AGENTES QUIMIOTERÁPICOS.

Investigador Principal: JOSÉ ANASTASIO MONTERO ARGUDO

CARDIOTOX CLÍNICO

Compartir la publicació